Odonate Therapeutics, Inc. Common Stock
ODT was delisted on the 14th of January, 2022.
57 hedge funds and large institutions have $541M invested in Odonate Therapeutics, Inc. Common Stock in 2019 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 20 increasing their positions, 20 reducing their positions, and 5 closing their positions.
50% more capital invested
Capital invested by funds: $361M → $541M (+$180M)
40% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 5
4% more funds holding
Funds holding: 55 → 57 (+2)
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
0% more repeat investments, than reductions
Existing positions increased: 20 | Existing positions reduced: 20
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OM
Opaleye Management
Boston,
Massachusetts
|
+$4.83M |
| 2 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
+$2.93M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$2.52M |
| 4 |
California Public Employees Retirement System
Sacramento,
California
|
+$1.22M |
| 5 |
Morgan Stanley
New York
|
+$727K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCM
Tang Capital Management
San Diego,
California
|
-$16.8M |
| 2 |
SM
Sabby Management
Miami Beach,
Florida
|
-$4.97M |
| 3 |
Allianz Asset Management
Munich,
Germany
|
-$1.42M |
| 4 |
SAAM
Solus Alternative Asset Management
Summit,
New Jersey
|
-$1.42M |
| 5 |
Franklin Resources
San Mateo,
California
|
-$668K |
ODT Hedge Fund Activity: Q1 2019 in Review
57 of the 4,620 institutional investors tracked by Wall St. Rank reported a position in Odonate Therapeutics, Inc. Common Stock (ODT) for Q1 2019, worth a combined $541M — up 50% from $361M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new ODT positions and 5 closed out — a net gain of 2 holders — while 20 added to existing stakes and 20 trimmed.
The largest buyer was Opaleye Management, adding an estimated $4.83M. The largest seller was Tang Capital Management, cutting an estimated $16.8M.
- 57 institutional investors held Odonate Therapeutics, Inc. Common Stock (ODT) as of Q1 2019, up from 55 in Q4 2018.
- Funds reported $541M of Odonate Therapeutics, Inc. Common Stock stock for Q1 2019, up 50% quarter-over-quarter.
- 7 funds opened new Odonate Therapeutics, Inc. Common Stock positions in Q1 2019 and 5 closed out, a net change of +2 holders.
- The largest Odonate Therapeutics, Inc. Common Stock buyer in Q1 2019 was Opaleye Management, an estimated $4.83M added.
- The largest Odonate Therapeutics, Inc. Common Stock seller in Q1 2019 was Tang Capital Management, an estimated $16.8M sold.
Based on aggregated 13F filings for Q1 2019.